Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydrofolate reductase pseudogene 3 (DHFRP3, hDHFR-psi 3) is a processed, intronless pseudogene associated with the DHFR gene family. Pseudogenes such as DHFRP3 arise through genomic duplication and subsequent loss of protein-coding potential. There are multiple DHFR-related pseudogenes in the human genome, commonly labeled as DHFRP1, DHFRP2, DHFRP3, and DHFRP4 (sometimes also referred to as DHFRL1)[6][7]. Unlike the functional DHFR enzyme, which is essential for folate metabolism and is a key drug target (especially in oncology and anti-infective therapy), DHFRP3 does not encode an active protein and is not implicated in any biological process, disease role, or drug response[2][6][7]. There is no evidence that DHFRP3 is expressed or encodes a functional protein, nor is there any indication that it serves as a direct therapeutic target, biomarker, or interacts with drugs. Only pseudogene DHFRL1 has been shown to have some expression and partial enzyme activity; the other pseudogenes, including DHFRP3, do not[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydrofolate reductase pseudogene 3 (DHFRP3).